This 24-year-old target demonstrates promise across multiple chronic diseases and has been prioritized by two AI-driven longevity companies. The quality of the chemistry will decide the winner.
Thanks Alex for this insightful analysis of the Inflammasome and its relevance to human biology - especially now the potential of NLRP3 ... I remember highlighting this many years ago when I was part of Pharma - that was not taken seriously. Glad that it is now getting its day in the sun! Best Wishes to you and InSilico ... Ravi Kiron
Once again, a cheap and effective solution already exists:
Vitamin D acts as a crucial negative regulator of the pro-inflammatory NLRP3 inflammasome, primarily through its receptor (VDR) binding directly to NLRP3, blocking its activation, and inhibiting the release of inflammatory cytokines like IL-1β and IL-18. This interaction reduces oxidative stress and dampens excessive inflammation seen in conditions like asthma, diabetes, and COVID-19, highlighting vitamin D as a potential therapeutic target against NLRP3-driven diseases.
As with GLP-1 therapies, the true value of NLRP3 inhibitors lies not in a single indication, but in their impact on chronic low-grade inflammation underlying aging, frailty, and multimorbidity. That said, lifestyle, nutrition, and physical exercise remain fundamental pillars in addressing inflammaging.
Thanks Alex for this insightful analysis of the Inflammasome and its relevance to human biology - especially now the potential of NLRP3 ... I remember highlighting this many years ago when I was part of Pharma - that was not taken seriously. Glad that it is now getting its day in the sun! Best Wishes to you and InSilico ... Ravi Kiron
Thank you, Ravi! It looks like this is one of the best molecules we have ever designed.
Once again, a cheap and effective solution already exists:
Vitamin D acts as a crucial negative regulator of the pro-inflammatory NLRP3 inflammasome, primarily through its receptor (VDR) binding directly to NLRP3, blocking its activation, and inhibiting the release of inflammatory cytokines like IL-1β and IL-18. This interaction reduces oxidative stress and dampens excessive inflammation seen in conditions like asthma, diabetes, and COVID-19, highlighting vitamin D as a potential therapeutic target against NLRP3-driven diseases.
As with GLP-1 therapies, the true value of NLRP3 inhibitors lies not in a single indication, but in their impact on chronic low-grade inflammation underlying aging, frailty, and multimorbidity. That said, lifestyle, nutrition, and physical exercise remain fundamental pillars in addressing inflammaging.